Eledon Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), a biopharmaceutical firm focused on autoimmune diseases and organ transplant treatments, will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 4:30pm EST. Interested participants can register here.

A replay will be available for 30 days on the company’s website. Eledon is developing AT-1501, an anti-CD40L antibody, for autoimmune diseases and transplants, aiming for improved safety and efficacy.

IRVINE, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30pm EST.

To register in advance for the corporate presentation, sign up here.

Replay Link:
A replay will be accessible for 30 days following the live session on the Events page of the Investors section on the Company’s website at https://ir.eledon.com/events-and-presentations/events.

About Eledon Pharmaceuticals and AT-1501

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company’s lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as B cells, macrophages, and dendritic cells. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which may also play a therapeutic role for autoimmune diseases and in the transplant setting. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: @Eledon_Pharma and LinkedIn.

Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com

FAQ

What is the date and time of Eledon Pharmaceuticals' presentation at the Jefferies Virtual Healthcare Conference?

Eledon Pharmaceuticals will present on June 1, 2021, at 4:30pm EST.

How can I access the replay of Eledon Pharmaceuticals' presentation?

A replay of the presentation will be available for 30 days on Eledon's website.

What is the main focus of Eledon Pharmaceuticals?

Eledon Pharmaceuticals is focused on developing treatments for autoimmune diseases, organ transplant patients, and ALS.

What is AT-1501 and its significance?

AT-1501 is Eledon's lead compound, an anti-CD40L antibody designed to improve safety and efficacy for autoimmune disease treatments.

Where is Eledon Pharmaceuticals headquartered?

Eledon Pharmaceuticals is headquartered in Irvine, California.